Â¥
9.91
Nov 29
Business Description
Jiangsu Wuzhong Pharmaceutical Development Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE000000YP4
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.81 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.97 | |||||
Debt-to-EBITDA | 40.91 | |||||
Interest Coverage | 0.52 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.57 | |||||
Beneish M-Score | -2.36 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.9 | |||||
3-Year EPS without NRI Growth Rate | 15.3 | |||||
3-Year FCF Growth Rate | 14.8 | |||||
3-Year Book Growth Rate | -1.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 21.2 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.24 | |||||
9-Day RSI | 50.18 | |||||
14-Day RSI | 50.21 | |||||
6-1 Month Momentum % | -2.23 | |||||
12-1 Month Momentum % | 10.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.5 | |||||
Quick Ratio | 1.46 | |||||
Cash Ratio | 0.72 | |||||
Days Inventory | 21.92 | |||||
Days Sales Outstanding | 167.22 | |||||
Days Payable | 50.25 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -1.06 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 28.8 | |||||
Operating Margin % | 1.69 | |||||
Net Margin % | -1.59 | |||||
FCF Margin % | -5.25 | |||||
ROE % | -2.13 | |||||
ROA % | -0.89 | |||||
ROIC % | 1.43 | |||||
ROC (Joel Greenblatt) % | 4.79 | |||||
ROCE % | 2.07 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 28.47 | |||||
PS Ratio | 3.02 | |||||
PB Ratio | 3.93 | |||||
Price-to-Tangible-Book | 5.03 | |||||
EV-to-EBIT | 172.88 | |||||
EV-to-EBITDA | 172.88 | |||||
EV-to-Revenue | 3.09 | |||||
EV-to-FCF | -57.72 | |||||
Price-to-Projected-FCF | 55.06 | |||||
Price-to-Median-PS-Value | 1.07 | |||||
Price-to-Net-Current-Asset-Value | 11.8 | |||||
Earnings Yield (Greenblatt) % | 0.58 | |||||
FCF Yield % | -1.77 | |||||
Forward Rate of Return (Yacktman) % | -4.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Jiangsu Wuzhong Pharmaceutical Development Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 2,383.922 | ||
EPS (TTM) (Â¥) | -0.052 | ||
Beta | 1.15 | ||
Volatility % | 45.13 | ||
14-Day RSI | 50.21 | ||
14-Day ATR (Â¥) | 0.393373 | ||
20-Day SMA (Â¥) | 10.0095 | ||
12-1 Month Momentum % | 10.78 | ||
52-Week Range (Â¥) | 6.9 - 13.88 | ||
Shares Outstanding (Mil) | 712.2 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Jiangsu Wuzhong Pharmaceutical Development Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Jiangsu Wuzhong Pharmaceutical Development Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Jiangsu Wuzhong Pharmaceutical Development Co Ltd Frequently Asked Questions
What is Jiangsu Wuzhong Pharmaceutical Development Co Ltd(SHSE:600200)'s stock price today?
When is next earnings date of Jiangsu Wuzhong Pharmaceutical Development Co Ltd(SHSE:600200)?
Does Jiangsu Wuzhong Pharmaceutical Development Co Ltd(SHSE:600200) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |